Frunevetmab (Solensia) for Feline Osteoarthritis: Effectiveness and Real-World Safety

Bottom line

• Frunevetmab is a felinized anti-nerve growth factor (anti-NGF) monoclonal antibody licensed for the alleviation of osteoarthritis pain in cats; it works by blocking nerve growth factor signaling.[1][2]
• In an observational real-world study, treatment with frunevetmab produced a statistically significant improvement in cats' quality of life across all measured domains by day 14, with the overall improvement exceeding the previously reported minimum important difference (a clinically significant change).[1]
• A pharmacovigilance analysis of the FDA Animal Drug Adverse Events database found that the most frequently reported adverse events were dermatological — pruritus, unspecified skin disorders, alopecia, dermatitis and eczema, and unspecified skin lesions.[2]
• That analysis also flagged adverse-event signals not listed in the package insert (including arthritis and paresis), which the authors describe as hypothesis-generating and in need of validation.[2]
• This page summarizes published evidence for licensed veterinary professionals; it is not a dosing guide, and all dosing must follow the current label and formulary.

Drug facts

• Class: Felinized anti-nerve growth factor (anti-NGF) monoclonal antibody (brand name Solensia)
• Mechanism: Binds nerve growth factor and blocks NGF signaling, a key driver of osteoarthritis-associated pain in cats[1][2]
• Route: Subcutaneous injection, given at monthly intervals[1]
• Indication: Alleviation of pain associated with osteoarthritis in cats[1][2]
• Dosing: Not specified here; follow the current label and formulary for the individual patient

A specific feline patient on frunevetmab or Solensia?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=frunevetmab-solensia-feline-osteoarthritis

What the evidence shows

Real-world effect on quality of life

Osteoarthritis causes chronic pain, impaired joint function, and reduced quality of life in cats. An observational, real-world study used a validated health-related quality-of-life instrument — generating domain scores for vitality, comfort, and emotional wellbeing in cats — to measure the impact of frunevetmab. Cats received frunevetmab by subcutaneous injection on a monthly schedule, and owners completed repeated quality-of-life assessments through a study app.[1]

Assessments were completed by 56 cat owners. By day 14 there was a statistically significant improvement in all quality-of-life domains and in the physical wellbeing summary score, with continued improvement at later time points. The overall improvement in domain scores in cats exceeded the previously reported minimum important difference for the measure, which the authors interpreted as a clinically significant change rather than a merely statistical one.[1] Because this was an observational design without a placebo arm, the results complement rather than replace the controlled registration studies.

Real-world safety signals from pharmacovigilance

A separate study analyzed spontaneous adverse-event reports for frunevetmab in cats from the United States FDA Animal Drug Adverse Events database, covering reports from January 2022 through December 2024. From a large pool of feline adverse-event reports, several thousand frunevetmab-specific reports were assessed using standard disproportionality methods.[2]

The most frequently reported adverse events were dermatological, including pruritus, unspecified skin disorders, alopecia, dermatitis and eczema, and skin lesions; the events with the highest signal strength included skin ulceration, injection-site pain, and dermatitis and eczema. The analysis also detected unexpected significant signals — including abnormal cytology, arthritis, and paresis — that were absent from the package insert.[2] The authors emphasize that disproportionality findings are hypothesis-generating: they identify reporting patterns that warrant clinical attention and further validation, and they cannot be read as incidence rates or as established causation.

Reading the two together

The effectiveness and safety literature point in complementary directions: a measurable, clinically meaningful improvement in quality of life on one hand, and a predominantly dermatological real-world adverse-event profile with a few unexpected signals on the other. Together they support frunevetmab as an effective option for feline osteoarthritis pain while underscoring the value of structured monitoring, particularly for skin and injection-site effects.[1][2]

How this fits clinical practice

This section summarizes the published evidence base for licensed practitioners and is not clinical guidance. Frunevetmab offers a monthly injectable option for cats with osteoarthritis pain, a population in which oral dosing and chronic NSAID use can be challenging. The real-world evidence supports a clinically meaningful quality-of-life benefit, while pharmacovigilance data suggest practitioners should counsel owners about dermatological and injection-site adverse effects and remain alert to less expected signals reported in post-marketing surveillance.

Dosing for an individual patient must follow the current label and formulary; this page does not provide dose recommendations. As always, monitoring and client communication should be tailored to the individual cat.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=frunevetmab-solensia-feline-osteoarthritis

References

1. Reid J, Gildea E, Davies V, Thompson J, Scott M. Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study. Front Vet Sci. 2024;11:1395360. https://pubmed.ncbi.nlm.nih.gov/39205806/
2. Lai X, Lin L, Chen Y, Wu L, Huang Y, Chen M. Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the FDA Animal Drug Adverse Events database. J Vet Intern Med. 2026;40(1):aalag003. https://pubmed.ncbi.nlm.nih.gov/41742572/

Changelog

• 2026-06-05: First published.

Related reads

• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile